Compare
Disc Medicine, Inc. vs Ocular Therapeutix, Inc vs MannKind Corp vs uniQure N.V.
| Latest fiscal year | Disc Medicine, Inc. IRON | Ocular Therapeutix, Inc OCUL | MannKind Corp MNKD | uniQure N.V. QURE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $51.95M | $348.97M | $16.10M |
| Revenue growth (YoY) | n/a | -18.5% | +22.2% | -40.6% |
| Gross margin | n/a | 87.3% (computed) | 92.3% (computed) | 89.5% (computed) |
| Operating margin | n/a | -519.8% | 11.1% | n/m |
| Net margin | n/a | -511.9% | 1.7% | n/m |
| Net income | -$212.18M | -$265.94M | $5.86M | -$198.97M |
| EPS (Diluted) | -$6.01 | -$1.42 | $0.02 | -$3.46 |
| Operating cash flow | -$180.39M | -$204.88M | $18.25M | -$177.96M |
| Free cash flow | -$181.33M | -$216.89M | $13.69M | -$178.40M |
| Cash & equivalents | $91.14M | $737.06M | $74.88M | $80.24M |
| Total assets | $806.88M | $808.06M | $792.18M | $824.91M |
| Total liabilities | $67.05M | $153.75M | $843.20M | $626.01M |
| Shareholders' equity | $739.83M | $654.31M | -$51.02M | $198.90M |
| Return on year-end equity | -28.7% | -40.6% | n/a | -100.0% |
| Shares outstanding | 37.89M | 215.93M | 307.83M | 62.34M |
Revenue, most recent five fiscal years
| Fiscal year | Disc Medicine, Inc. | Ocular Therapeutix, Inc | MannKind Corp | uniQure N.V. |
|---|---|---|---|---|
| Latest | n/a | $51.95M Ended 2025-12-31 | $348.97M Ended 2025-12-31 | $16.10M Ended 2025-12-31 |
| 1 year earlier | n/a | $63.72M Ended 2024-12-31 | $285.50M Ended 2024-12-31 | $27.12M Ended 2024-12-31 |
| 2 years earlier | n/a | $58.44M Ended 2023-12-31 | $198.96M Ended 2023-12-31 | $15.84M Ended 2023-12-31 |
| 3 years earlier | n/a | $51.49M Ended 2022-12-31 | $99.77M Ended 2022-12-31 | $106.48M Ended 2022-12-31 |
| 4 years earlier | n/a | $43.52M Ended 2021-12-31 | $75.44M Ended 2021-12-31 | $524.00M Ended 2021-12-31 |